Rechercher des projets européens

34 projets européens trouvés

Recherche sur 125080 projets européens

 TERMINÉ 

Applied Public-Private Research enabling OsteoArthritis Clinical Headway (APPROACH)

Date du début: 1 juin 2015, Date de fin: 30 nov. 2020,

The problem: finding the right patient for the right treatmentDespite a large and growing disease burden in osteoarthritis (OA), many pharmaceutical companies have de-emphasized or even abandoned OA drug development due to perceived hurdles. Crucial in this is the lack of appropriate outcome measures that can robustly identify patient benefit from a specific therapy. The lack of specific and sensi ...
Voir le projet

 25

 TERMINÉ 

Pharmaceutical Education And Research with Regulatory Links: Innovative drug development strategies and regulatory tools tailored to facilitate earlier access to medicines (PEARRL)

Date du début: 1 mai 2016, Date de fin: 30 avr. 2020,

The European Pharma industry is a major contributor to EU well-being, both in public health and economic (sales >200 billion €/year) terms. To maintain global leadership, it must respond to challenges from low-cost producers e.g. China by bringing new drug molecules to market in a streamlined, cost-effective manner. This strategy is underscored by recent initiatives of European regulators to exped ...
Voir le projet

 9

 TERMINÉ 

Sustainable downstream processing of vaccines through incorporation of nanobiotechnologies : novel affinity ligands and biomimetic membranes (DiViNe)

Date du début: 1 mars 2015, Date de fin: 29 févr. 2020,

In the vaccine industry, downstream processing is of extreme importance. Prophylactic vaccines aim at protecting healthy people, so any contaminant has to be discarded with the most drastic measures. Such « negative » approach comes at the expense of the recovery of product : yields are poor, thereby inducing a high product cost. Processes are also complex, since they rely on multiple eliminations ...
Voir le projet

 6

 TERMINÉ 

Development of high-performance, hyperfluorescence OLEDs for use in display applications and solid state lighting (HyperOLED)

Date du début: 1 janv. 2017, Date de fin: 31 déc. 2019,

The overall goal of the HyperOLED project is to develop materials and matching device architectures for high-performance, hyperfluorescence organic light emitting diodes (OLEDs) for use in display applications and solid state lighting. The innovative OLEDs will be realised by combining thermally activated delayed fluorescence (TADF) molecular hosts with novel shielded fluorescence emitters, target ...
Voir le projet

 5

 TERMINÉ 

Production technology to achieve low Cost and Highly Efficient phOtovoltaic Perovskite Solar cells (CHEOPS)

Date du début: 1 févr. 2016, Date de fin: 31 janv. 2019,

The aim of CHEOPS is to develop very low-cost but highly performing photovoltaic (PV) devices based on the emerging perovskite (PK) technology. At lab scale (20%. But only few attempts at upscaling have been made, yielding significantly reduced efficiencies 14% stable for aperture area in modules >15x15cm2). This will demonstrate the potential of PK as a very low-cost technology (target 29% on 2x2 ...
Voir le projet

 13

 TERMINÉ 

Advanced high-resolution printing of organic Transistors for Large Area Smart Surfaces (ATLASS)

Date du début: 1 mars 2015, Date de fin: 31 août 2018,

Bringing intelligence and communication to everyday objects is a major challenge for future electronics. This « Internet of Things » concept envisions wide dissemination with new performances: robustness, large area, flexibility, eco-efficient large volume manufacturing at low cost. Beyond current TOLAE demonstration, a major technology jump driving the scalability towards nanoscale resolution via ...
Voir le projet

 17

 TERMINÉ 

European Medical Information Framework (EMIF)

Date du début: 1 janv. 2013, Date de fin: 31 déc. 2017,

In response to the need to tackle increasingly complex medical research questions, a growing amount of human health data is being collected, either in routine Electronic Healthcare Record (EHR) databases, through research-driven cohort studies, in biobanks or related efforts. However, data sources are typically fragmented and contain information gaps which prevent their full exploitation. EMIF aim ...
Voir le projet

 64

 TERMINÉ 

European Lead Factory (EUC²LID)

Date du début: 1 janv. 2013, Date de fin: 31 déc. 2017,

The European Lead Factory concept proposed by the EUC2LID Consortium relates to the discovery of novel small molecule candidates to serve as starting points for subsequent optimization to either drug candidates or high-quality pharmacological tools for the experimental validation of targets. The concept intends to bridge academic and applied research interests. The European Lead Factory will provi ...
Voir le projet

 34

 TERMINÉ 

QUantitative Imaging in Cancer: CONnecting CEllular Processes with Therapy (QUIC-CONCEPT)

Date du début: 1 sept. 2011, Date de fin: 31 déc. 2017,

The QuIC-ConCePT consortium has 2 objectives: 1.(90% of resource, WP2-5) to qualify 3 specific imaging biomarkers (IBs) of tumour cell proliferation, apoptosis, and necrosis, to allow drug developers to demonstrate reliably modulation of these pathologic processes in tumours in patients in realistic trials. Our vision for January 2016 is that drug developers can incorporate these IBs for decision- ...
Voir le projet

 26

 TERMINÉ 

Kinetics for Drug Discovery (K4DD) (K4DD)

Date du début: 1 nov. 2012, Date de fin: 31 oct. 2017,

There is mounting evidence that the often ignored kinetic aspects of the interaction between a drug and its target are highly relevant for clinical success. This ignorance may be one of the reasons for the high attrition rates in drug discovery, as it has been analyzed that many recently marketed drugs had indeed improved kinetic profiles. This hindsight knowledge needs to be converted into data-d ...
Voir le projet

 21

 TERMINÉ 

Collaboration on the Optimisation of Macromolecular Pharmaceutical Access to Cellular Targets (COMPACT)

Date du début: 1 nov. 2012, Date de fin: 31 oct. 2017,

Most biopharmaceuticals (BP) currently on the market are recombinant proteins which are parenterally administered. These would benefit from more patient-friendly routes of administration. Moreover, new classes of BP (e.g. siRNA, miRNA, DARPins) with specificity for intracellular targets hold promise but await the advent of efficient delivery systems before their potential can be realised into ther ...
Voir le projet

 22

 TERMINÉ 

Delivering European Translational Information & Knowledge Management Services (ETRIKS)

Date du début: 1 oct. 2012, Date de fin: 30 sept. 2017,

Since its inception the IMI has funded over 30 public-private partnership projects. Many of these projects are centered upon data intensive translational research and are employing integrative analysis approaches to achieve their goals. Although a common KM platform for IMI projects was envisioned in the original IMI Strategic Research Agenda it has not yet been implemented. The lack of a common p ...
Voir le projet

 17

 TERMINÉ 

Stem cells for Biological Assays of Novel drugs and prediCtive toxiCology (StemBANCC) (STEMBANCC)

Date du début: 1 oct. 2012, Date de fin: 30 sept. 2017,

StemBANCC, comprising internationally renowned investigators, is ideally positioned to deliver a unique European biorepository and drug discovery pipeline based upon human induced pluripotent stem cells (hiPSC). This unrivalled opportunity will address the pressing therapeutic need in neurodegeneration, neurodysfunction and diabetes. We have immediate access to richly phenotyped subjects with a we ...
Voir le projet

 38

 TERMINÉ 

BeTheCuRE (BTCURE)

Date du début: 1 avr. 2011, Date de fin: 31 mars 2017,

BTCure is based on the recognition that RA is a heterogeneous disease where a major subset involves adaptive immunity, and that animal models have to develop the line with the different subsets of the human diseases in order to be optimally used for drug discovery and drug evaluation. Our aim is to develop an understanding of the early process in human arthritis subsets and the animal models that ...
Voir le projet

 41

 TERMINÉ 

Anti-Biopharmaceutical Immunization:Prediction and analysis of clinical relevance to minimize the risk (ABIRISK)

Date du début: 1 mars 2012, Date de fin: 28 févr. 2017,

The ABIRISK project provides an integrated approach to the study of immunization against biopharmaceuticals, bringing together a unique panel of experts from different disciplines. ABIRISK will involve many of the European leaders in rheumatology, gastroenterology, hemophilia and multiple sclerosis, caring for ~30,000 patients treated with biopharmaceuticals, with ~10,000 additional patients recru ...
Voir le projet

 39

 TERMINÉ 

European Patients' Academy on Therapeutic Innovation (EUPATI)

Date du début: 1 févr. 2012, Date de fin: 31 janv. 2017,

"The proposed project ""European Patients' Academy on Therapeutic Innovation"" (EUPATI) contributes to IMI’s goal of raising patients’ awareness and participation in pharmaceutical R&D. This patient-led academy will provide scientifically reliable, objective, comprehensive information to patients on pharmaceutical R&D. It will increase the capacity of well-informed patients to be effective advocat ...
Voir le projet

 33

 TERMINÉ 

Mechanism-Based Integrated Systems for the Prediction of Drug-Induced Liver Injury (MIP-DILI)

Date du début: 1 févr. 2012, Date de fin: 31 janv. 2017,

The current test systems employed by Industry are poorly predictive for Drug induced liver injury (DILI). The ‘MIP-DILI’ project will address this situation by the development of innovative preclinical test systems which are both mechanism-based and of physiological, pharmacological and pathological relevance to DILI in humans. An iterative, tiered approach with respect to test compounds, test sys ...
Voir le projet

 29

 TERMINÉ 

OncoTrack - Methods for systematic next generation oncology biomarker development (ONCOTRACK)

Date du début: 1 janv. 2011, Date de fin: 31 déc. 2016,

We propose here an exhaustive analysis of the genome, exome, methylome and transcriptome of primary tumours and metastases from patients with colon carcinoma, based on a combination of deep sequencing and chip based techniques. Dependent on their availability, we shall also perform analyses of tumor stem cells, circulating tumor cells, free tumor DNA in serum and xenografts derived from the same p ...
Voir le projet

 22

 TERMINÉ 

Incorporating real-life clinical data into drug development (GETREAL)

Date du début: 1 oct. 2013, Date de fin: 31 déc. 2016,

When a new medicine reaches the market, it is accompanied by an extensive data package that provides information about the safety and efficacy of the medicine in a clinical trial setting. However, assessing the expected future value of the medicines when used in “real world” clinical practice requires additional information next to traditional (pre-authorisation) clinical trials. Regulatory, HTA ...
Voir le projet

 32

 TERMINÉ 

European Modular Education and Training Programme in Safety Sciences for Medicines (SAFESCIMET)

Date du début: 1 janv. 2010, Date de fin: 30 nov. 2016,

Background:In current drug safety education and training in Europe, an integrative and translational approach is lacking. This shortfall has been identified by EUFEPS. The IMI (‘Strategic Research Agenda’), the FDA and the EMEA have also characterised this fact as a crucial gap in the education and training of scientists evaluating the safety of drug candidates and new medicines. Scope and objecti ...
Voir le projet

 34

 TERMINÉ 

OFET biosensors for point-of-care applications (sense-of-care)

Date du début: 1 déc. 2012, Date de fin: 30 nov. 2016,

Electronic, label-free biosensors characterized by rapidity and detection proved to be very promising being able to directly detect biological recognition events without the need of markers. In this respect, organic bioelectronics has gained a huge interest among scientists coming from different disciplines and sectors due to its high impact on medical, clinical, food and environmental fields. Pre ...
Voir le projet

 3

 TERMINÉ 

Drug Disease Model Resources (DDMORE)

Date du début: 1 mars 2011, Date de fin: 31 août 2016,

Model based-drug development (MBDD) is accepted as a vital approach in understanding patient risk/benefit and attrition. At the core of MBDD lies Modelling and Simulation (M&S), a technology providing the basis for informed, quantitative decision-making.M&S facilitates the continuous integration of available information related to a drug or disease into constantly-evolving mathematical models capa ...
Voir le projet

 28

 TERMINÉ 

The Open Pharmacological Concepts Triple Store (OPEN PHACTS)

Date du début: 1 mars 2011, Date de fin: 29 févr. 2016,

Drug discovery is data-hungry and all major pharmaceutical companies maintain extensive in-house instances of public data alongside internal. Analysis and hypothesis generation for drug-discovery projects requires assembly, overlay and comparison of data from many sources, requiring shared identifiers and common semantics. Expression profiles need to be overlaid with gene or pathway identifiers an ...
Voir le projet

 32

 TERMINÉ 

Electronic Health Record systems for Clinical Research (EHR4CR)

Date du début: 1 mars 2011, Date de fin: 29 févr. 2016,

Current medical needs, the growth of targeted therapies and personalized medicines, and escalating R&D costs result in formidable cost pressures on healthcare systems and the pharmaceutical industry. Clinical research is also growing in complexity, labour intensity and cost. There is a growing realization that the development and integration of Electronic Health Record systems (EHRs) for medical ...
Voir le projet

 37

 TERMINÉ 

Integrated In Silico Models for the Prediction of Human Repeated Dose Toxicity of Cosmetics to Optimise Safety (COSMOS)

Date du début: 1 janv. 2011, Date de fin: 31 déc. 2015,

The COSMOS project will address the assessment needs of the cosmetics industry by delivering an integrated suite of computational tools to predict the effects of long-term exposure to cosmetic ingredients in humans, thus reducing the need for repeated dose toxicity testing in animals. To achieve this, individual modules comprising: (new) databases, thresholds of toxicological concern (TTC), in sil ...
Voir le projet

 15

 TERMINÉ 

Prediction of cognitive properties of new drug candidates for neurodegenerative diseases in the early clinical development (PHARMA-COG)

Date du début: 1 janv. 2010, Date de fin: 31 déc. 2015,

PHARMA-COG aims to develop a new integrated model to accelerate the development of drug cindidates for MS, PKD and AD. The innovation relies on a 'multidimensional matrix' approach, integrating all available and renewed inputs (biomarkers/animal, human models/physiological and pharmcological challenges, Phase 0/1/1b to reduce the attrition rate, to allow an early and pertinent GO/NOGO decision bef ...
Voir le projet

 38

 TERMINÉ 

DEVELOPMENT OF NEW UV LASER FOR CUSTOMIZATION AT INDUSTRIAL LEVEL THROUGH HIGH QUALITY MARKING ON DIFFERNT MATERIALS (UV-Marking)

Date du début: 1 juil. 2012, Date de fin: 31 oct. 2015,

...ID will work in the field of glass and ceramic materials. Finally, 3 different groups of ICMA (from University of Zaragoza and CSIC) will participate as experts on laser and materials.The company Merck has also contributed to UV-Marking during the first months of the project, before the incorporation of DATALASE.
Voir le projet

 12

 TERMINÉ 

Development and scale-up of nanostructured based materials and processes for low cost high efficiency chalcogenide based photovoltaics (SCALENANO)

Date du début: 1 févr. 2012, Date de fin: 31 juil. 2015,

This project will exploit the potential of chalcogenide based thin film photovoltaic technologies for the development and scale-up of new processes based on nanostructured materials for the production of high efficiency and low cost photovoltaic devices and modules compatible with mass production requirements. Cu(In,Ga)(S,Se)2 (CIGS) chalcogenide based devices have the highest efficiency of all th ...
Voir le projet

 14

 TERMINÉ 

Pharmacoepidemiolocal Research on Outcomes of Therapeutics by a European ConsorTium (PROTECT)

Date du début: 1 sept. 2009, Date de fin: 30 avr. 2015,

Recent pharmacovigilance (PV) issues have led to questions regarding the ability of the current PV system to meet the global needs. Controversies around the assessment of spontaneous reports and conflicting results from pharmacoepidemiology studies may lead to delay in, or inappropriate, regulatory decisions. The PROTECT consortium, consisting of 20 core partners lead by the European Medicines Age ...
Voir le projet

 36

 TERMINÉ 

Pharmaceutical Medicine Training Programme (PHARMATRAIN)

Date du début: 1 mai 2009, Date de fin: 30 avr. 2014,

"The proposed Pharmaceutical Medicine Training Programme provides a comprehensive solution for the complex needs of integrated drug development for all professionals involved, incl. physicians, pharmaceutical scientists,biologists, biometricians, health economists, and safety and regulatory scientists from universities, regulatory agencies, large, middle-sized and small pharmaceutical enterprises, ...
Voir le projet

 52

 TERMINÉ 

EUROpean multilevel integrated BIOREFinery design for sustainable biomass processing (EuroBioRef)

Date du début: 1 mars 2010, Date de fin: 28 févr. 2014,

The development and implementation of bio-refinery processes is an absolute necessity and the key to meet the vision towards bio-based economy. The EuroBioRef concept is an integrated, sustainable and diversified bio-refinery involving all biomass value chain stakeholders. The latter will allow large-scale research, testing, optimisation and demonstration of processes in the production of a wide r ...
Voir le projet

 34

 TERMINÉ 

Profiling the toxicity of new drugs: a non animal-based approach integrating toxicodynamics and biokinetics (Predict-IV)

Date du début: 1 mai 2008, Date de fin: 31 oct. 2013,

The overall aim of Predict-IV is to develop strategies to improve the assessment of drug safety in the early stage of development and late discovery phase, by an intelligent combination of non animal-based test systems, cell biology, mechanistic toxicology and in-silico modelling, in a rapid and cost effective manner. A better prediction of the safety of an investigational compound in early develo ...
Voir le projet

 20

 TERMINÉ 

Advanced Magnetic nanoparticles deliver smart Processes and Products for Life (MagPro²Life)

Date du début: 1 juil. 2009, Date de fin: 30 juin 2013,

Biotechnologically derived substances for large scale feed, food and pharma applications represent one of the most important sources of new products due to their precisely controlled structural and functional properties, potential for economic and responsible production and overall broad benefits to society through biocompatibility and sustainability. The costs of producing biomaterials are in man ...
Voir le projet

 16

 TERMINÉ 

Organic Nanomaterials for Electronics and Photonics: Design, Synthesis, Characterization, Processing, Fabrication and Applications (ONE-P)

Date du début: 1 janv. 2009, Date de fin: 31 déc. 2011,

The call 4.2.2-1 “organic materials for electronics and photonics” is based on the observation that the limited availability of high-performance multi-functional materials is a roadblock to further industrial progress. To address the wide scope of the call, we have identified specific materials bottlenecks to the fields of electronics and photonics. They constitute the focal points of our project. ...
Voir le projet

 31